Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Phytomedicine ; 107: 154468, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36209702

ABSTRACT

BACKGROUND: Ulcerative colitis (UC) has affected an increasing number of people globally, with still limited clinical success. Huanglian Decoction (HLD) is a famous classical prescription documented for alleviating gastrointestinal disorders with unexplored therapeutic effects and mechanisms. PURPOSE: This study aimed to investigate the therapeutic effect and underlying mechanism of HLD in dextran sodium sulfate (DSS)-induced colitis mice. METHODS: The efficacy and safety of HLD were evaluated in a well-established DSS-induced colitis mice model. Disease progression was monitored via clinical symptoms, histopathological examination, biochemical assays, and epithelial barrier function evaluation. RESULTS: HLD alleviated DSS-induced colitis symptoms, reversed colon length reduction, reduced histological injury, downregulated the level of pro-inflammatory cytokines, maintained the tight distribution of ZO-1/occludin-1 and the normal level of ß-catenin, concurrent with apoptosis reduction in the colonic epithelium. After HLD treatment, the DSS-induced gut dysbiosis was modulated, and the gut microbiota achieved a new equilibrium state. CONCLUSION: This study demonstrates that HLD may present a potential remedy for UC treatment, providing evidence for further developing Chinese classical prescriptions.


Subject(s)
Colitis, Ulcerative , Colitis , Gastrointestinal Microbiome , Animals , Colitis/chemically induced , Colitis, Ulcerative/chemically induced , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/pathology , Colon/pathology , Cytokines , Dextran Sulfate/adverse effects , Disease Models, Animal , Drugs, Chinese Herbal , Mice , Mice, Inbred C57BL , Occludin , Prescriptions , beta Catenin
2.
Zhonghua Yi Shi Za Zhi ; 50(5): 275-282, 2020 Sep 28.
Article in Chinese | MEDLINE | ID: mdl-33287494

ABSTRACT

Rehmanniae Radix (Dihuang in Chinese) is a commonly used medicinal herb in a long history, raw Dihuang, dried Dihuang, processed Dihuang and other varieties have been recorded in the classical prescriptions of past dynasties. In order to clarify the origin and variety evolution of different processed products of Dihuang in Chinese classical prescriptions, ancient herbal books were examined in this paper. Both ancient and modern Dihuang is derived from Rehmannia glutinosa Libosch. in Scrophulariaceae, and R. chingii Li has been used as local medication. Dihuang has been cultivated since the Southern and Northern Dynasties, and the cultivation technique was mature in the Tang and Song Dynasties. Huaiqing Prefecture of Henan Province has been regarded as its genuine producing area. "Dried Dihuang" in Shennong Bencao Jing(, Shennong's Classic of Materia Medica) included raw Dihuang and processed Dihuang. Mingyi Bielu(, Alternative Records of Famous Physicians) has described "raw Dihuang" and "Dried Dihuang" separately, in which "raw Dihuang" should be fresh Dihuang in modern times. Bencao Tujing(, Illustration of Materia Medica) in the Song Dynasty has recorded "raw Dihuang" and "processed Dihuang" correspondingly. The "raw Dihuang" was similar to today's raw Dihuang. "Processed Dihuang" has been recorded in the prescriptions of the Qin and Han Dynasties, which was independently described in the Song Dynasty. The processing methods of processed Dihuang were various in the Ming Dynasty. Processed Dihuang mainly refers to the dried products after stewing with wine or steaming until dark, and the processing methods tend to be simplified in modern times. "Raw and dried Dihuang" and "dried and processed Dihuang" have been independently recorded first in ancient herbal books of the Ming Dynasty, which is the raw Dihuang and processed Dihuang, respectively. This paper has sorted out the varieties of Dihuang, providing a basis of herbology for the origin and processing of traditional Chinese medicinal materials of Dihuang.


Subject(s)
Drugs, Chinese Herbal , Medicine, Chinese Traditional/history , Plants, Medicinal , China , History, 15th Century , History, 16th Century , History, Medieval , Humans , Prescriptions
3.
Zhongguo Zhong Yao Za Zhi ; 45(13): 3028-3034, 2020 Jul.
Article in Chinese | MEDLINE | ID: mdl-32726008

ABSTRACT

With the global outbreak of coronavirus disease 2019(COVID-19), screening of effective drugs has became the emphasis of research today; furthermore, screening of Chinese classic prescriptions has became one of the directions for drug development. This study analyzed the application of classic prescriptions in the diagnosis and treatment schemes based on the Diagnosis and Treatment Schemes for Coronavirus Disease at the country, provincial and municipal levels, and further explored its disrobing effect on COVID-19 disease severe phase network, and selected representative prescriptions for core target screening and gene enrichment analysis, so as to reveal its mechanism of action. Among them, 13 prescriptions were found to be used for 10 times or more, including Maxing Shigan Tang, Yinqiao San, Shengjiang San, Dayuan Drink, Xuanbai Chengqi Decoction. In addition, the COVID-19 efficacy prediction analysis platform(TCMATCOV platform) was used to calculate the network disturbances of the Chinese classic prescriptions involved. Based on the prediction results, 68 classic prescriptions were assessed on the COVID-19 disease network robustness disturbance. The average disturbance scores for the interaction confidence scores were ranked to be 0.4, 0.5, and 0.6 from the highest to the lowest. There were 7 prescriptions with a score of 17 or more, and 50 prescriptions with a score of 13 or more. Among them, the top three prescriptions were Ganlu Xiaodu Dan(18.19), Lengxiao Wan(17.74), and Maxing Shigan Tang(17.62). After further mining the action targets of these three prescriptions, it was found that COVID-19 disease-specific factors Ccl2, IL10, IL6 and TNF were all the targets of three prescriptions. Through the enrichment analysis of the biological processes of the core targets, it was found that the three prescriptions may prevent the development of the disease by affecting cell-to-cell adhesion, cytokine-mediated signaling pathway, and chronic inflammatory responses to COVID-19 at the severe phase. This study showed that the TCMATCOV platform could evaluate the disturbance effect of different prescriptions on the COVID-19 disease network, and predict potential effectiveness based on the robustness of drug-interfered pneumonia disease networks, so as to provide a reference for further experiments or clinical verification.


Subject(s)
Betacoronavirus , Coronavirus Infections , Drugs, Chinese Herbal , Pandemics , Pneumonia, Viral , COVID-19 , Coronavirus Infections/drug therapy , Humans , Medicine, Chinese Traditional , Pneumonia, Viral/drug therapy , SARS-CoV-2 , COVID-19 Drug Treatment
4.
Zhongguo Zhong Yao Za Zhi ; 45(7): 1707-1716, 2020 Apr.
Article in Chinese | MEDLINE | ID: mdl-32489053

ABSTRACT

Through consulting the ancient herbs and medical books, combining with modern literature, this paper makes textual research on herbal medicine, and textual research on the name, origin, position and harvest and processing changes of the medicinal herbs in ancient classical prescriptions. According to research, Cinnamon medicinal materials were first listed in the Shennong's Herbal Classic, as the name of "Jungui" and "Mugui". Among them, Jungui has undergone the evolution of "Qungui-Jungui-Tonggui-Jungui". After the Northern and Southern Dynasties, a half-volume fatty "Gui" was added, but the usage of the three was no different. The names of Cinnamomi Ramulus and Cinnamomi Cortex did not appear until the Tang Dynasty, and they were preferably thick-skinned and with no cork cambium, and they were mostly used in the name of "Guixin"; Since the Song and Yuan Dynasties, the medicinal parts of cassia have gradually separated. Cinnamomi Cortex is the trunk bark of sapling or branch bark, the twig is Cinnamomi Ramulus, and the tenderest twig is Liugui, Song Dynasty unified the name as "Guizhi"; After the Ming and Qing Dynasties, Cinnamomi Cortex was used as the trunk bark, and Cinnamomi Ramulus was used as the tender twig; In modern times, the Chinese Pharmacopoeia stipulates that the Cinnamomi Ramulus is the young branch of C. cassia, which is Cinnamomum, and Cinnamomi Cortex was the dried trunk bark. From the plant morphology recorded in the previous herbals and the drawings, combined with the distribution of the origins described in the previous herbals, the mainstream plant used as a medicine in the past generations should be C. cassia, but there are other sect. Cinnamomum plants that are also used in medicine everywhere, such as C. chekiangensis, C. bejolghota, C. wilsonii, etc. Throughout the ages, different plant morphologies and medicinal traits have been used to distinguish different categories. The origins of the past dynasties are mostly present in Guangdong, Guangxi province and Vietnam, and are regarded as authentic. The methods for the harvest and processing of cinnamon medicinal materials are basically the same from ancient to modern times.


Subject(s)
Drugs, Chinese Herbal , Plants, Medicinal , China , Herbal Medicine , Medicine, Chinese Traditional , Phytotherapy , Vietnam
5.
Zhongguo Zhong Yao Za Zhi ; 45(3): 697-703, 2020 Feb.
Article in Chinese | MEDLINE | ID: mdl-32237531

ABSTRACT

Through consulting the herbs and medical books of past dynasties, combining with modern literature and field investigation, this paper made textual research on the name, origin, producing area, harvesting and processing of Bupleuri Radix used in the Catalogue of Ancient Classical Prescriptions(the first batch).From Han to the Southern and Northern Dynasties, the source of Bupleuri Radix was a mixture of Bupleurum and Peucedanum, it's hard to define the origin of authentic products.In Tang Dynasty, Caryophyllaceae had been used as Bupleuri Radix. In Song Dynasty, it was clear that the genuine production area of Bupleuri Radix was Yinzhou, its origin was B. corzonerifolium and B. yinchowense.After the Ming Dynasty, B. chinense gradually became the mainstream. It has been confirmed that there were differences in the efficacy between Stellaria dichotoma in Caryophyllaceae and Bupleurum in Umbelliferae, however, the use of S. dichotoma is still attributed to Bupleuri Radix. In the Qing Dynasty, S. dichotoma was distinguished from Bupleuri Radix as another medicine. Among the prescriptions containing Bupleuri Radix included in the Catalogue of Classical Prescriptions in Ancient China(the first batch), the mainstream of genuine Bupleuri Radix should be B. scorzonerifolium and B. chinense. It is suggested that the genuine base of Bupleuri Radix should be selected according to the current resources and industrial development of Bupleuri Radix, and it should conform to the Chinese Pharmacopoeia.


Subject(s)
Bupleurum/chemistry , Drugs, Chinese Herbal , Plant Roots/chemistry , China , Medicine, Chinese Traditional , Prescriptions
6.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-1008556

ABSTRACT

Through consulting the herbs and medical books of past dynasties, combining with modern literature and field investigation, this paper made textual research on the name, origin, producing area, harvesting and processing of Bupleuri Radix used in the Catalogue of Ancient Classical Prescriptions(the first batch).From Han to the Southern and Northern Dynasties, the source of Bupleuri Radix was a mixture of Bupleurum and Peucedanum, it's hard to define the origin of authentic products.In Tang Dynasty, Caryophyllaceae had been used as Bupleuri Radix. In Song Dynasty, it was clear that the genuine production area of Bupleuri Radix was Yinzhou, its origin was B. corzonerifolium and B. yinchowense.After the Ming Dynasty, B. chinense gradually became the mainstream. It has been confirmed that there were differences in the efficacy between Stellaria dichotoma in Caryophyllaceae and Bupleurum in Umbelliferae, however, the use of S. dichotoma is still attributed to Bupleuri Radix. In the Qing Dynasty, S. dichotoma was distinguished from Bupleuri Radix as another medicine. Among the prescriptions containing Bupleuri Radix included in the Catalogue of Classical Prescriptions in Ancient China(the first batch), the mainstream of genuine Bupleuri Radix should be B. scorzonerifolium and B. chinense. It is suggested that the genuine base of Bupleuri Radix should be selected according to the current resources and industrial development of Bupleuri Radix, and it should conform to the Chinese Pharmacopoeia.


Subject(s)
Bupleurum/chemistry , China , Drugs, Chinese Herbal , Medicine, Chinese Traditional , Plant Roots/chemistry , Prescriptions
7.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-828019

ABSTRACT

With the global outbreak of coronavirus disease 2019(COVID-19), screening of effective drugs has became the emphasis of research today; furthermore, screening of Chinese classic prescriptions has became one of the directions for drug development. This study analyzed the application of classic prescriptions in the diagnosis and treatment schemes based on the Diagnosis and Treatment Schemes for Coronavirus Disease at the country, provincial and municipal levels, and further explored its disrobing effect on COVID-19 disease severe phase network, and selected representative prescriptions for core target screening and gene enrichment analysis, so as to reveal its mechanism of action. Among them, 13 prescriptions were found to be used for 10 times or more, including Maxing Shigan Tang, Yinqiao San, Shengjiang San, Dayuan Drink, Xuanbai Chengqi Decoction. In addition, the COVID-19 efficacy prediction analysis platform(TCMATCOV platform) was used to calculate the network disturbances of the Chinese classic prescriptions involved. Based on the prediction results, 68 classic prescriptions were assessed on the COVID-19 disease network robustness disturbance. The average disturbance scores for the interaction confidence scores were ranked to be 0.4, 0.5, and 0.6 from the highest to the lowest. There were 7 prescriptions with a score of 17 or more, and 50 prescriptions with a score of 13 or more. Among them, the top three prescriptions were Ganlu Xiaodu Dan(18.19), Lengxiao Wan(17.74), and Maxing Shigan Tang(17.62). After further mining the action targets of these three prescriptions, it was found that COVID-19 disease-specific factors Ccl2, IL10, IL6 and TNF were all the targets of three prescriptions. Through the enrichment analysis of the biological processes of the core targets, it was found that the three prescriptions may prevent the development of the disease by affecting cell-to-cell adhesion, cytokine-mediated signaling pathway, and chronic inflammatory responses to COVID-19 at the severe phase. This study showed that the TCMATCOV platform could evaluate the disturbance effect of different prescriptions on the COVID-19 disease network, and predict potential effectiveness based on the robustness of drug-interfered pneumonia disease networks, so as to provide a reference for further experiments or clinical verification.


Subject(s)
Humans , Betacoronavirus , Coronavirus Infections , Drug Therapy , Drugs, Chinese Herbal , Medicine, Chinese Traditional , Pandemics , Pneumonia, Viral , Drug Therapy
8.
Zhongguo Zhong Yao Za Zhi ; 44(23): 5248-5255, 2019 Dec.
Article in Chinese | MEDLINE | ID: mdl-32237364

ABSTRACT

Through consulting the ancient herbs and medical books,combining with modern literature and field investigation,this paper makes textual research on herbal medicine,and makes textual research on the name,origin,position and changes of collection and processing of the medicinal herbs in Ancient Classical Prescriptions. " Zhu" wasn't distinguished before the Northern and Southern Dynasties,but the efficacy of the techniques recorded in the documents at that time was similar to that of today's Atractylodis Rhizoma.Tao Hongjing put forward the theory of " red and white" in the Northern and Southern Dynasties. " Cangzhu" and " Baizhu" gradually differentiated,but there was no clear distinction between them. Since Song and Yuan Dynasties, " Baizhu" has been respected and classified in the literature. In Ming Dynasty, " Baizhu" was cultivated and differentiated into different quality specifications according to its growth pattern and origin. Maoshan is the genuine production area of " Cangzhu". The quality of wild " Baizhu" produced in Yuqian city is the best. In modern times,the origins of " Cangzhu" and " Baizhu" were defined according to plant taxonomy. " Zhu" before Song Dynasty was close to Atractylodes lancea, " Baishu" had been respected since the Song Dynasty. So when Song people revised the previous literature,they unified " Zhu" into " Baizhu" and used it for later generations. Its safety and effectiveness have been confirmed,and the wild resources of modern atractylodes are scarce. Therefore,it is suggested that when classical famous prescriptions are developed,the prescription recorded as " Baizhu" does not need to be changed in its origin,that is,A. macrocephala at present or can choose the appropriate basis according to the principle of local righteousness.Textual research shows that the origin of " Cangzhu" in the classical prescription should be A. lancea.


Subject(s)
Atractylodes/classification , Drugs, Chinese Herbal , Medicine, Chinese Traditional , Plants, Medicinal/classification , Atractylodes/chemistry , China , Phytotherapy , Plants, Medicinal/chemistry , Rhizome
9.
Zhongguo Zhong Yao Za Zhi ; 44(24): 5496-5502, 2019 Dec.
Article in Chinese | MEDLINE | ID: mdl-32237400

ABSTRACT

In this paper,the name,origin,producing area,harvesting and processing changes of Paeonia lactiflora used in classical prescriptions were studied by textual research of herbal medicine and field investigation. Chinese herbaceous peony wasn' t distinguished before the Northern and Southern Dynasties; Tao Hongjing proposed that there were two kinds of P. lactiflora in the Northern and Southern Dynasties,but they were not clearly defined; since the Song and Yuan Dynasties,the method of distinguishing P. lactiflora by flower color and root color was proposed. In the Ming Dynasty,people put forward the criteria similar to modern ones,that is,to divide red peony and white peony by means of harvesting and processing,and to continue for future generations. Since modern times,different growth patterns and processing methods have been used to classify red peony and white peony. Paeoniae Radix Alba has gradually formed three major cultivation genuine producing areas: Hangzhou,Sichuan and Bozhou,while Paeoniae Radix Rubra in modern times has praised the wild medicinal materials produced in Inner Mongolia,Toronto and other places. According to textual research,Paeoniae Radix Alba was highly praised in Song Dynasty. When people in Song Dynasty revised the previous literature,they changed " Shaoyao" into " Baishao" and continued to use Paeoniae Radix Alba for future generations. Therefore,the origin of P. lactiflora in classical prescriptions before the Song Dynasty should be determined by the combination of prescription function and prescription meaning evolution; After the Song Dynasty,the origins of " Red Paeonia Root" and " White Paeonia Root" in prescriptions are basically the same as those in today's prescriptions,which should be recorded in ancient prescriptions. For the medicinal flavor of " Paeonia Root" recorded in prescriptions after the Song Dynasty,the origins can be determined by functional domination and the evolution of prescriptions.


Subject(s)
Drugs, Chinese Herbal/history , Paeonia , Plants, Medicinal , China , History, 15th Century , History, 16th Century , History, 17th Century , History, Medieval , Humans , Phytotherapy
10.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-1008426

ABSTRACT

In this paper,the name,origin,producing area,harvesting and processing changes of Paeonia lactiflora used in classical prescriptions were studied by textual research of herbal medicine and field investigation. Chinese herbaceous peony wasn' t distinguished before the Northern and Southern Dynasties; Tao Hongjing proposed that there were two kinds of P. lactiflora in the Northern and Southern Dynasties,but they were not clearly defined; since the Song and Yuan Dynasties,the method of distinguishing P. lactiflora by flower color and root color was proposed. In the Ming Dynasty,people put forward the criteria similar to modern ones,that is,to divide red peony and white peony by means of harvesting and processing,and to continue for future generations. Since modern times,different growth patterns and processing methods have been used to classify red peony and white peony. Paeoniae Radix Alba has gradually formed three major cultivation genuine producing areas: Hangzhou,Sichuan and Bozhou,while Paeoniae Radix Rubra in modern times has praised the wild medicinal materials produced in Inner Mongolia,Toronto and other places. According to textual research,Paeoniae Radix Alba was highly praised in Song Dynasty. When people in Song Dynasty revised the previous literature,they changed " Shaoyao" into " Baishao" and continued to use Paeoniae Radix Alba for future generations. Therefore,the origin of P. lactiflora in classical prescriptions before the Song Dynasty should be determined by the combination of prescription function and prescription meaning evolution; After the Song Dynasty,the origins of " Red Paeonia Root" and " White Paeonia Root" in prescriptions are basically the same as those in today's prescriptions,which should be recorded in ancient prescriptions. For the medicinal flavor of " Paeonia Root" recorded in prescriptions after the Song Dynasty,the origins can be determined by functional domination and the evolution of prescriptions.


Subject(s)
Humans , China , Drugs, Chinese Herbal/history , History, 15th Century , History, 16th Century , History, 17th Century , History, Medieval , Paeonia , Phytotherapy , Plants, Medicinal
11.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-1008390

ABSTRACT

Through consulting the ancient herbs and medical books,combining with modern literature and field investigation,this paper makes textual research on herbal medicine,and makes textual research on the name,origin,position and changes of collection and processing of the medicinal herbs in Ancient Classical Prescriptions. " Zhu" wasn't distinguished before the Northern and Southern Dynasties,but the efficacy of the techniques recorded in the documents at that time was similar to that of today's Atractylodis Rhizoma.Tao Hongjing put forward the theory of " red and white" in the Northern and Southern Dynasties. " Cangzhu" and " Baizhu" gradually differentiated,but there was no clear distinction between them. Since Song and Yuan Dynasties, " Baizhu" has been respected and classified in the literature. In Ming Dynasty, " Baizhu" was cultivated and differentiated into different quality specifications according to its growth pattern and origin. Maoshan is the genuine production area of " Cangzhu". The quality of wild " Baizhu" produced in Yuqian city is the best. In modern times,the origins of " Cangzhu" and " Baizhu" were defined according to plant taxonomy. " Zhu" before Song Dynasty was close to Atractylodes lancea, " Baishu" had been respected since the Song Dynasty. So when Song people revised the previous literature,they unified " Zhu" into " Baizhu" and used it for later generations. Its safety and effectiveness have been confirmed,and the wild resources of modern atractylodes are scarce. Therefore,it is suggested that when classical famous prescriptions are developed,the prescription recorded as " Baizhu" does not need to be changed in its origin,that is,A. macrocephala at present or can choose the appropriate basis according to the principle of local righteousness.Textual research shows that the origin of " Cangzhu" in the classical prescription should be A. lancea.


Subject(s)
Atractylodes/classification , China , Drugs, Chinese Herbal , Medicine, Chinese Traditional , Phytotherapy , Plants, Medicinal/classification , Rhizome
SELECTION OF CITATIONS
SEARCH DETAIL
...